Pulse Biosciences Inc (PLSE) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Pulse Biosciences Inc (PLSE) has a cash flow conversion efficiency ratio of -0.183x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-14.76 Million) by net assets ($80.66 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See net asset quality index of Pulse Biosciences Inc to measure how much of total assets are equity-financed.
Pulse Biosciences Inc - Cash Flow Conversion Efficiency Trend (2014–2025)
This chart illustrates how Pulse Biosciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore PLSE operating cash flow to total debt to assess how comfortably operating cash covers total debt obligations.
Pulse Biosciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Pulse Biosciences Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Westamerica Bancorporation
NASDAQ:WABC
|
0.032x |
|
Orchid Island Capital Inc.
NYSE:ORC
|
0.035x |
|
Jiangsu Wujiang Rural Coml Bk
SHG:603323
|
-0.276x |
|
Aygaz AS
IS:AYGAZ
|
0.003x |
|
Herbalife Nutrition Ltd
F:HOO
|
-0.229x |
|
Ipsos SA
PA:IPS
|
0.069x |
|
Liberty Latin America Ltd Class C
NASDAQ:LILAK
|
0.041x |
|
Dalian Bio-Chem Co Ltd
SHG:603360
|
0.098x |
Annual Cash Flow Conversion Efficiency for Pulse Biosciences Inc (2014–2025)
The table below shows the annual cash flow conversion efficiency of Pulse Biosciences Inc from 2014 to 2025. For the full company profile with market capitalisation and key ratios, see market value of Pulse Biosciences Inc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $80.66 Million | $-54.12 Million | -0.671x | -112.08% |
| 2024-12-31 | $114.86 Million | $-36.34 Million | -0.316x | +57.52% |
| 2023-12-31 | $44.36 Million | $-33.04 Million | -0.745x | -103.56% |
| 2022-12-31 | $-2.25 Million | $-47.01 Million | 20.913x | +1479.73% |
| 2021-12-31 | $35.69 Million | $-54.10 Million | -1.516x | +1.88% |
| 2020-12-31 | $22.89 Million | $-35.37 Million | -1.545x | -38.89% |
| 2019-12-31 | $30.74 Million | $-34.19 Million | -1.112x | -208.73% |
| 2018-12-31 | $66.33 Million | $-23.90 Million | -0.360x | -49.45% |
| 2017-12-31 | $45.99 Million | $-11.09 Million | -0.241x | +24.26% |
| 2016-12-31 | $25.30 Million | $-8.05 Million | -0.318x | -31.12% |
| 2015-12-31 | $13.67 Million | $-3.32 Million | -0.243x | -2153.35% |
| 2014-12-31 | $16.07 Million | $-173.14K | -0.011x | -- |
About Pulse Biosciences Inc
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers nPulse System, a novel Nanosecond Pulsed-Field Ablation delivery platform to treat benign lesions of the skin; nPulse Vybrance Percutaneous Electrode system for soft tissue ablation in surgical setting; nPulse Cardiac Surgical Clamp designed for use in surgical treatment of atrial fibrillation (AF); nPulse Cardiac… Read more